8OHdG is not a biomarker for Huntington disease state or progression

Neurology. 2013 May 21;80(21):1934-41. doi: 10.1212/WNL.0b013e318293e1a1. Epub 2013 Apr 24.


Objective: To evaluate plasma 8-hydroxy-deoxy-guanosine (8OHdG) levels as a potential biomarker of premanifest and early Huntington disease (HD).

Methods: Personnel from 2 independent laboratories quantified 8OHdG in blinded longitudinal plasma samples taken 24 months apart from 160 TRACK-HD participants, as well as samples containing control plasma with added ("spiked") 8OHdG. One laboratory used a liquid chromatography-electrochemical array (LCECA) assay, and the other used liquid chromatography-mass spectrometry (LCMS).

Results: The LCMS assay was more accurate than the LCECA assay for measurements of "spiked" 8OHdG levels in plasma. Neither assay demonstrated cross-sectional differences in plasma 8OHdG among controls, premanifest HD, and early symptomatic HD. Similarly, neither assay showed longitudinal changes in any disease group over 24 months.

Conclusions: Plasma concentration of 8OHdG is not a biomarker of disease state or progression in HD. We recommend that future putative biomarker studies use blinded sample analysis, standard curves, independent analytical methods, and strict quality control of sample collection and storage.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Adult
  • Biomarkers / blood
  • Deoxyguanosine / analogs & derivatives*
  • Deoxyguanosine / blood
  • Disease Progression*
  • Female
  • Humans
  • Huntington Disease / blood
  • Huntington Disease / diagnosis*
  • Huntington Disease / pathology*
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prospective Studies
  • Single-Blind Method


  • Biomarkers
  • 8-Hydroxy-2'-Deoxyguanosine
  • Deoxyguanosine